linjc16/ctgov huggingface dataset:
Study of Immune Thrombocytopenia Pathogenesis:

Study Overview
=================
Brief Summary
-----------------
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells. However, T cells are also involved but their role is not completely understood. The aim of this study is to determine the implication of T cells in the pathogenesis of ITP, notably regulatory T cells (Treg, CD4+CD25highFoxp3+), cytotoxic T cells (CD3+CD8+) and T follicular helper cells (TFH, CD3+CD4+CXCR5+PD-1+ICOS+), in blood and in the spleen of primary ITP patients, compared to healthy controls.

Official Title
-----------------
Study of Immune Thrombocytopenia Pathogenesis: a Multicenter, Open and Controlled Study.

Conditions
-----------------
Primary Immune Thrombocytopenia (ITP)

Intervention / Treatment
-----------------
* Other: Blood samples
* Other: Spleen samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with ITP, defined as thrombocytopenia < 30 G/L, once causes related to infection, medication, systemic auto-immune disease or malignant hemopathy have been ruled out persons who have provided written informed consent Exclusion Criteria: persons without national health insurance persons under 18 years old patients under guardianship pregnancy subjects suffering from a systemic auto-immune disease, cancer, a progressive infection, or treated with steroids or immunosuppressants.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with ITP<br> | Other: Blood samples<br> <br> Other: Spleen samples<br> <br> |
| Controls<br> | Other: Blood samples<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood level T cell in ITP patients and in healthy controls |  | baseline | 
| blood level T cell in ITP patients after treatments |  | change from baseline at 4 to 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood level splenic T cell in ITP patients and in healthy controls |  | baseline | 
| frequency of innate immune cells (dendritic cells, monocytes, NK cells…) and their functions in blood and spleens, in patients and in controls |  | through study completion, an average of 3 years | 
| level of T follicular helper cell |  | through study completion, an average of 3 years |
A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether BMS068645 is as effective as Adenosine SPECT at detecting blockages in heart arteries, and to determine if it will have fewer side effects

Official Title
-----------------
A Phase 3, Parallel, Double Blind, Multicenter Trial to Examine Inducible Myocardial Perfusion Abnormality Detection With BMS068645 and Adenosine Stress SPECT Compared to Coronary Angiography

Conditions
-----------------
Heart Disease, Ischemic Heart Disease

Intervention / Treatment
-----------------
* Drug: apadenoson


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Referral for pharmacologic stress SPECT MPI Have suspected Ischemic heart disease Exclusion Criteria: Acute myocardial Infarction, Coronary artery bypass graft, percutaneous coronary intervention within 30 days of enrollment Severe asthma or COPD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: apadenoson|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of BMS068645 vs. adenosine; to be determined at the end of the study after enrollment is complete |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of serious adverse events due to adenosine vs. BMS068645; incidence of adverse events due to adenosine vs. BMS068645; to be determined at the end of the study after enrollment, but with interim independent analysis by a safety monitoring board |  |  |
Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Study Overview
=================
Brief Summary
-----------------
Therapeutic equivalence and safety study

Detailed Description
-----------------
To evaluate the therapeutic equivalence and safety of Test formulation and marketed Reference Listed Drug (RLD). To demonstrate the superiority of efficacy of the Test and Reference products over the placebo control in the treatment. To compare the safety of Test, Reference and Placebo treatments.

Official Title
-----------------
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Test Gel, 5% to ACZONE Gel, 5% and Both Active Treatment to a Placebo Control in the Treatment of Acne Vulgaris

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Drug: Test.
* Drug: Aczone Gel 5%
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male or non pregnant female aged ≥ 12 and ≤ 40years with a clinical diagnosis of acne vulgaris Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigator's Global Assessment (IGA) (per Table 1 below) Exclusion Criteria: Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test Gel 5%<br>Topical, twice daily on the face for 84 days. | Drug: Test.<br>* gel<br>* Other names: dapsone;|
| Active Comparator: ACZONE Gel 5%<br>Topical, twice daily on the face for 84 days | Drug: Aczone Gel 5%<br>* gel<br>* Other names: dapsone;|
| Placebo Comparator: Placebo Gel<br>Topical, twice daily on the face for 84 days | Drug: Placebo<br>* gel<br>* Other names: Vehicle;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in inflammatory lesion count |  | baseline to week 12 (study day 84) | 
| Change in non-inflammatory lesion count |  | baseline to week 12 (study day 84) |
Pulmonary Hypertension Registry Switzerland

Study Overview
=================
Brief Summary
-----------------
Registry Data from PH-patients in Switzerland, who have given consent to records for research purposes.

Official Title
-----------------
Swiss PH Registry - Cohort of Swiss PH Patients

Conditions
-----------------
Pulmonary Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with PH Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pulmonary arterial hypertension<br>Pulmonary arterial hypertension | |
| PH due to left heart diseases<br>PH due to left heart diseases | |
| PH due to lung disease and/or hypoxia<br>PH due to lung disease and/or hypoxia | |
| Chronic thromboembolic PH<br>Chronic thromboembolic PH | |
| Miscellaneous PH<br>Miscellaneous PH | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6-minute walking distance | 6-minute walking distance | within the study duration e.g. up to 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New York Heart Association functional class | New York Heart Association functional class | within the study duration e.g. up to 10 years | 
| NTproBNP | NTproBNP | within the study duration e.g. up to 10 years | 
| Survival | time to death analysis | within the study duration e.g. up to 10 years | 
| Medication | escalation of clinical therapy | within the study duration e.g. up to 10 years |
Comparison of Aqueous and Plasma Glucose Level in Diabetic Patients

Study Overview
=================
Brief Summary
-----------------
Comparison of aqueous and plasma glucose level in diabetic patients High glucose concentrations in aqueous humor are thought to be related of diabetic ocular injury, including cataract and diabetic keratopathy. The primary mechanisms are nonenzymatic glycation, oxidative stress and activation of polyol pathway. However, glucose concentrations in aqueous humor of diabetic patients was only examined in a few patients in the past. This study will compare glucose concentration in blood plasma and aqueous humor in diabetic patients undergoing cataract surgery. Perioperative Hemoglobin A1c concentrations will also be examined. Correlation between these parameters will be analyzed.

Official Title
-----------------
Comparison of Aqueous and Plasma Glucose Level in Diabetic Patients

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: Glucose measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Diabetic patients planed for elective cataract surgery Exclusion Criteria: s/p traumatic eye injury past or current uveitis patients using prescription eye drops except lubricants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diabetic patients<br>Diabetic patients planned to undergo elective cataract surgery | Other: Glucose measurement<br>* Elective cataract surgery Blood glucose measurement - glucometer Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer Perioperative Hemoglobin A1c level - blood laboratory test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aqueous humor glucose concentration |  | Day of cataract surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma glucose concentrations |  | Day of cataract surgery | 
| Hemoglobin A1c |  | Perioperative month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes Mellitus, Cataract, Aqueous humor
Patient Perspective of Telemedicine in Gynecology Oncology

Study Overview
=================
Brief Summary
-----------------
Research question: do patients in a gynecologic oncology practice value the use of telemedicine as an adjunct to in-person visits and in what circumstances might patients not find these visits to be sufficient?

Detailed Description
-----------------
In the United States, 14.8 million women live greater than 50 miles away from the closest gynecology oncologist underscoring the need for increased implementation of telemedicine. In consideration of the COVID-19 outbreak, recommendations were made to organize goals of therapy by prioritizing curative intent and utilizing telemedicine to manage current therapies. Research regarding telemedicine, its benefits, and patient perspectives in other specialties has been reported, however there appears to be a dearth of information in the field of gynecologic oncology. Our study aims to seek patients' perspective of telemedicine and whether implementation for extended office visits, teleconsultations and more are feasible and valuable to them.

Official Title
-----------------
Patient Perspective of Telemedicine in Gynecology Oncology

Conditions
-----------------
Oncology

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
o Eligible patients would be at least 18 years of age, and currently being treated by one of the providers within the gynecologic oncology group.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Survey|o We plan to hand out copies of a survey to examine patient's perspective on telemedicine.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient's perspective on telemedicine on a Likert Scale | Patient's perspective on telemedicine on a Likert Scale | Through survey completion, an average of 15 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Telemedicine
Comparison of 2 Ventilatory Support Strategies During Coronavirus Disease 2019 (Covid-19) Pneumonia

Study Overview
=================
Brief Summary
-----------------
This retrospective monocentric study compares 2 ventilatory support strategies on outcomes (length of stay, intubation, mortality) in patients admitted in Intensive Care Unit with Covid-19 related pneumonia : invasive strategy used during the first period and non-invasive strategies (Continuous Positive Airway Pressure, High Flow Nasal Canula, Prone Position) used during the second period.

Official Title
-----------------
Comparison of 2 Ventilatory Support Strategies in Patients With Covid-19 Pneumonia Admitted in ICU : Retrospective Monocentric Study

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Procedure: Invasive ventilation strategy
* Procedure: Non-invasive ventilation strategies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with confirmed SARS COV2 infection Acute Respiratory Distress Syndrome Patient more than 18 year old Exclusion Criteria: Intensive Care Unit admission for extra pulmonary failure Do Not Reanimated order Patient from another Intensive Care Unit Patient objection Judicial protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Invasive strategy group<br>Patients admitted in ICU with Covid-19 related pneumonia during COVID19 first period. | Procedure: Invasive ventilation strategy<br>* Use of an invasive ventilatory support strategy<br>|
| Non-invasive strategy group<br>Patients admitted in ICU with Covid-19 related pneumonia during COVID19 second period. | Procedure: Non-invasive ventilation strategies<br>* Use of non-invasive ventilatory support strategies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stay in ICU | Number of days spent in ICU | At the moment of ICU discharge or death, up to 3 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Rate of patients alive at the moment of intensive care unit discharge | At the moment of ICU discharge or death, up to 3 month | 
| Complications | Number of complications during intensive care unit stay | At the moment of ICU discharge or death, up to 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Continuous Positive Airway Pressure, High Flow Nasal Canula, Prone position, Invasive strategy, Non-invasive strategy
Impact of Left Atrial Function on Postoperative Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
We aimed to demonstrate the impact of left atrial functions which were evaluated by three different echocardiographic modalities , on postoperative atrial fibrillation.

Detailed Description
-----------------
Postoperative atrial fibrillation after coronary artery bypass greft operation (CABG) is major complication with a prevalence of 10-50%. Although the men mechanism is not known, in recent studies, age and left atrial function have been demonstrated as the most responsible factors. Velocity vector imaging (VVI) is a new modality which may give accurate and detailed information on both left atrial segmental and global function. In this study, our aim was to assess preoperative left atrial function by using three different echocardiographic modalities, VVI, tissue Doppler imaging and conventional echocardiography and evaluate the relation between the left atrial functions and the development of post-operative atrial fibrillation after CABG.

Official Title
-----------------
Impact Of Velocity Vector Imaging, Tissue Doppler Imaging, Conventional Echocardiography And P Wave Dispertion In Evaluating Post-Operative Atrial Fibrillation After Coronary Bypass Graft Surgery

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1Coronary artery disease evidenced by coronary angiography 2Patients with a decision of undergoing elective coronary artery bypass greft operation 3Sinus rhythm in electrocardiography Exclusion Criteria: 1Rheumatic valve disease 2Having prosthetic valve 3CABG accompanied by other cardiac interventions (such as valvular surgery, ASD closure...etc) 4Left ventricular l ejection fraction <40% 5Mild to moderate mitral stenosis or regurgitation 6Having atrial fibrillation or a history of atrial fibrillation attach during the last two weeks. 7Congenital heart disease 8Chronic liver disease 9Chronic renal disease 10Malignancy

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with postoperative atrial fibrillation | |
| 2<br>Patients without postoperative atrial fibrillation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Velocity vector imaging derived left atrial segmenter function, Tissue doppler derved left atrial segmenter function, conventional analysis of atrial function by 2D and pulsed wave echocardiography. |  | April 2008 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atrial fibrillation, left atrium, velocity vector imaging
A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis

Study Overview
=================
Brief Summary
-----------------
Stenosis of the renal graft arteries occurs in 1 to 26% of cases and can damage the graft. Endovascular treatment is first-line treatment. The main objective of this study is to identify the predictive factors of failure of peri-anastomotic.

Detailed Description
-----------------
The aim of this study was to evaluate the post-operative outcomes following endovascular treatment of TRAS (Transplant Renal Artery Stenosis). This retrospective, monocentric study included patients with peri-anastomotic stenosis of the renal graft from 2000 to 2017. The stenosis is defined by a reduction of at least 50% of the arterial diameter during arteriography. Technical success was defined as residual stenosis less than 30% of the arterial diameter after the procedure.

Official Title
-----------------
A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis: Evaluation of Post-operative Outcomes

Conditions
-----------------
Unrecognized Condition

Intervention / Treatment
-----------------
* Procedure: Angioplasty for Transplant Renal Artery Stenosis (TRAS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who had a renal transplant from brain-dead donors or from living donors All patients who had a Transplant Renal Artery Stenosis Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Angioplasty for Transplant Renal Artery Stenosis (TRAS)|The angioplasty is an endovascular treatment for artery stenosis, which could be associated with stenting or not.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The technical success rate of endovascular treatment | The stenosis is defined by a reduction of at least 50% of the arterial diameter during arteriography. Technical success was defined as residual stenosis less than 30% of the arterial diameter after the procedure | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morbidity rate | Morbidity rate is defined as the development of post-operative complications. Minor and major complications are recorded, corresponding to Clavien Dindo classification | 30 days | 
| Mortality rate | All death are recorded to identify the mortality rate | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transplant renal artery stenosis, Endovascular repair, Post-operative outcome